Full Press Release Details
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Myeloma--Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior...
BMY Positive Sentiment
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
Key Takeaway: Bristol Myers Squibb has announced that ZENBEXUSTM (iberdomide), in combination with Daratumumab and Dexamethasone, has demonstrated superior progression-free survival compared to standard care in patients with relapsed and refractory multiple myeloma. This finding comes from a Phase 3 clinical trial, highlighting the potential of this combination therapy to improve treatment outcomes for patients.
Market Sentiment Analysis
POSITIVE FACTORS
- ZENBEXUSTM shows superior progression-free survival.
- Combination therapy is promising for relapsed and refractory multiple myeloma.
- Phase 3 results indicate potential for improved patient outcomes.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+16%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Pneumococcal polysaccharide vaccine
Phase 3 · Multiple Sclerosis
Frequently Asked Questions
What is ZENBEXUSTM?
ZENBEXUSTM (iberdomide) is a treatment for multiple myeloma.
How does ZENBEXUSTM compare to standard care?
ZENBEXUSTM demonstrates superior progression-free survival compared to standard care.
What was the phase of the clinical trial?
The clinical trial for ZENBEXUSTM was a Phase 3 study.
What combination was tested with ZENBEXUSTM?
ZENBEXUSTM was tested in combination with Daratumumab and Dexamethasone.